Astonea Labs Share Price Today | Stock Price & Astonea Labs Share Screener
Track the current Astonea Labs share price and stock price live with TickJournal's free stock screener. Check Astonea Labs yearly highs lows for the annual price range and momentum. Use the Astonea Labs stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Astonea Labs opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Key Statistics and Valuation Ratios
Astonea Labs Share Price Chart
Track the current stock price of Astonea Labs with an interactive chart. Analyse ASTONEALAB share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Astonea Labs stock quote in one place.
Astonea Labs Company Profile - Fundamental Screener
Screen Astonea Labs company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for ASTONEALAB shares across the equity market and its stock price history, plus the wider market trend.
The company is classified under the Healthcare sector and the Pharmaceuticals industry, and it trades under ISIN INE0TG901011.
Company Details
Classification
Identifiers and Leadership
Astonea Labs Balance Sheet Screener
Screen ASTONEALAB balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.
For 2026, total assets were ₹146, up from ₹103 in 2025.
Latest statistics put total assets at ₹146 and shareholder funds at ₹57, with a leverage ratio of 1.28.
| Item | 2026 | 2025 |
|---|---|---|
Assets |
||
| Total Assets | 146 | 103 |
| Current Assets | 98 | 71 |
| Fixed Assets | 31 | 26 |
Liabilities |
||
| Total Liabilities | 0 | 0 |
| Current Liabilities | 21 | 20 |
| Non-Current Liabilities | 0 | 0 |
Shareholders' Equity |
||
| Total Equity | 57 | 18 |
| Share Capital | 11 | 8 |
| Reserves & Surplus | 47 | 11 |
Astonea Labs Income Statement Screener - Profit & Revenue Analysis
Screen Astonea Labs income statement and profit fundamentals. Analyze ASTONEALAB quarterly results. Astonea Labs reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.
For None-None, revenue was ₹0 and net profit was ₹0.
In that period expenses were ₹0, interest cost ₹0 and tax ₹0. The next period listed, 2026-March, shows revenue of ₹148 and net profit of ₹5.
| Item | None-None | 2026-March | 2025-March |
|---|---|---|---|
Revenue and Expenses | |||
| Revenue | 0 | 148 | 98 |
| Expenses | 0 | 134 | 82 |
Operating Costs and Margins | |||
| EBITDA | 0 | 14 | 15 |
| Operating Profit % | 0.00% | 9.00% | 16.00% |
| Depreciation | 0 | 5 | 5 |
| Interest | 0 | 3 | 4 |
Profit and Earnings | |||
| Profit Before Tax | 0 | 6 | 7 |
| Tax | 0 | 1 | 2 |
| Net Profit | 0 | 5 | 5 |
| EPS | 0.00 | 4.49 | 6.94 |
Astonea Labs Cash Flow Screener - Liquidity Fundamentals
Screen ASTONEALAB cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.
In 2026-March, operating activities used ₹14.
Over the same period, investing activities used ₹20 and financing activities provided ₹34.
| Item | 2026-March | 2025-March |
|---|---|---|
Cash from Operations and Investing | ||
| Operating Activities | -14 | 9 |
| Investing Activities | -20 | -11 |
Financing and Net Cash | ||
| Financing Activities | 34 | 2 |
| Net Cash Flow | 0 | 0 |
Astonea Labs Shareholding Pattern Screener
See Astonea Labs shareholding pattern with promoter, FII, and DII holdings. Check Astonea Labs promoter holding and ownership changes for ASTONEALAB on TickJournal, and see how institutional stock price moves affect the market.
In 2026-Mar, promoters held 72.30%, foreign institutions 0.00%, domestic institutions 0.07% and the public 22.25%, spread across 376 shareholders.
The shareholder count was 376 in 2026-Mar, compared with 36 in 2025-May.
| Item | 2026-Mar | 2025-May | 2025-Jun | 2025-Sept | 2024-Aug |
|---|---|---|---|---|---|
Promoter Holding | |||||
| Promoter Holding | 72.30% | 72.30% | 72.30% | 72.30% | 98.43% |
Institutional Investors | |||||
| FII Holding | 0.00% | 0.00% | 8.01% | 2.51% | 0.00% |
| DII Holding | 0.07% | 0.00% | 4.55% | 0.35% | 0.00% |
Government, Public and Others | |||||
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 22.25% | 12.24% | 11.51% | 17.06% | 0.00% |
| Other Holding | 5.38% | 15.45% | 3.62% | 7.77% | 1.57% |
| Shareholder Count | 376 | 36 | 1,014 | 437 | 36 |
Dividend Yield Screener - Share Price & Share Analysis
Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Astonea Labs. Astonea Labs dividend yield can be compared with peers and other stocks in the market.
Astonea Labs Stock Index Membership - Nifty & Sensex
See which indices include Astonea Labs stock. Check ASTONEALAB index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.
The company is listed in 1 indices, including BSE SME IPO.
Complete Index List
Astonea Labs Market Events Screener - Corporate Actions
Get Astonea Labs corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Astonea Labs stock events that may affect ASTONEALAB share price, along with derivatives, futures and options activity and sector gainers.
7 corporate actions are listed, the most recent entry being Annual General Meeting dated August 21, 2026, with a record date of August 21, 2026.
It is followed by Quarterly Result Announcement dated July 24, 2026 and Quarterly Result Announcement dated May 30, 2026.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-08-21 | 2026-08-21 | Annual General Meeting | NA | 6.59% |
| 2026-07-24 | 2026-07-24 | Quarterly Result Announcement | NA | -5.85% |
| 2026-05-30 | 2026-05-30 | Quarterly Result Announcement | NA | 1.56% |
| 2026-03-27 | 2026-03-27 | Extraordinary General Meeting | NA | 1.29% |
| 2025-12-27 | 2025-12-27 | Annual General Meeting | NA | 6.70% |
| 2025-11-10 | 2025-11-10 | Quarterly Result Announcement | NA | 2.50% |
| 2025-07-11 | 2025-07-11 | Quarterly Result Announcement | NA | 3.94% |
Astonea Labs Competitors Screener - Peer Stocks Comparison
Screen ASTONEALAB competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.
The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 447,476 | 36.44 | 61,674 | 12.69% | 11,565 | 47.42 |
| Divis Laboratories | 250,363 | 86.51 | 11,067 | 13.95% | 2,568 | 58.71 |
| Torrent Pharmaceuticals | 186,152 | 85.91 | 13,886 | 20.34% | 2,138 | 48.14 |
| Zydus Life Science | 120,798 | 26.32 | 27,658 | 17.64% | 5,026 | 61.81 |
| Cipla | 111,426 | 33.44 | 29,045 | 2.24% | 3,870 | 44.03 |
| Laurus Labs | 106,838 | 99.70 | 6,868 | 22.01% | 890 | 58.00 |
| Mankind Pharma | 105,107 | 48.73 | 14,636 | 14.85% | 1,938 | 64.24 |
| Dr Reddys Laboratories | 104,492 | 32.05 | 35,059 | 3.90% | 4,158 | 69.59 |
| Aurobindo Pharma | 97,682 | 26.36 | 34,145 | 5.56% | 3,503 | 54.69 |
| Lupin | 93,829 | 16.99 | 29,039 | 26.75% | 5,356 | 34.02 |
Astonea Labs Company Announcements - News & Reports Screener
Screen ASTONEALAB latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.
20 recent announcements are listed, the latest dated October 2, 2026.
The next most recent announcements are dated September 29, 2026 and September 26, 2026.
| Date | Update | Actions |
|---|---|---|
| 2026-10-02 | Closure of Trading Window | - |
| 2026-09-29 | Resubmission Of Financial Results For The Half Year Ended 31.03.2025 In Response To BSE Communication | - |
| 2026-09-26 | Resubmission Of Financial Results For The Financial Year Ended 31.03.2025 In Response To BSE Communication | - |
| 2026-09-18 | Disclosures under Reg. 29(1) of SEBI (SAST) Regulations 2011 | - |
| 2026-09-17 | Submission Of Disclosure Under Regulation 7(2) Of The SEBI (Prohibition Of Insider Trading) Regulation 2015. | - |
| 2026-09-17 | Disclosures Under Regulation 29(1) Of SEBI (Substantial Acquisition Of Shares & Takeovers) Regulations 2011. | - |
| 2026-09-09 | Appointment Of Internal Auditor | - |
| 2026-09-09 | Board Meeting Outcome for Meeting Held On 9Th September 2026. | - |
| 2026-08-21 | Announcement under Regulation 30 (LODR)-Amendments to Memorandum & Articles of Association | - |
| 2026-08-21 | Re-Appointment Of Ms. Pooja Singh As Director Of The Company | - |
| 2026-08-21 | Shareholder Meeting / Postal Ballot-Scrutinizers Report | - |
| 2026-08-21 | Shareholder Meeting / Postal Ballot-Outcome of AGM | - |
| 2026-07-25 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-07-24 | Reg. 34 (1) Annual Report. | - |
| 2026-07-24 | Notice Of 9Th Annual General Meeting ("AGM") Of The Company For The Financial Year 2025-26 | - |
| 2026-07-24 | Revision In Re-Appointment Of Tax Auditor | - |
| 2026-07-24 | Audited Consolidated Financial Results For The Half Year And Year Ended 31.03.2026 | - |
| 2026-07-24 | Board Meeting Outcome for Board Meeting Outcome For Meeting Held On 24Th July 2026 | - |
| 2026-07-18 | Board Meeting Intimation for Approval Of Audited Consolidated Financial Results For The Financial Year Ended 31.03.2026 And Others. | - |
| 2026-07-17 | Intimation Under Regulation 30-Execution And Registration Of Sale Deed For Sale Of Immovable Properties. | - |
Frequently Asked Questions
How is the company valued right now?
The P/B ratio is 6.22. Market capitalisation stands at ₹355.30 Cr. The company operates in the Healthcare sector, in the Pharmaceuticals industry, so compare these ratios with its sector peers in the table above.
About This Data
Key statistics were last updated on October 6, 2026. This page covers 2 balance sheet periods, 3 income statement periods, 2 cash flow years and 5 shareholding periods. Information is provided for research and is not investment advice.